Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Benzinga Newsdesk www.benzinga.com Positive 88.4%

Neg 0% Neu 0% Pos 88.4%

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.